MET and lung adenocarcinoma: The potential for sequential use of combinatorial therapy of osimertinib and cabozantinib has also been demonstrated in a case study where a patient with EGFR-mutated lung adenocarcinoma acquired four MET mutations upon crizotinib treatment [22].